(MedPage Today) — The nitric oxide-independent soluble guanylate cyclase activator ataciguat continued to show promise for slowing the progression of fibrocalcific aortic valve stenosis in phase I and II studies. (Circulation)
The extent of myocardial…
Source link : https://www.medpagetoday.com/cardiology/prevention/114364
Author :
Publish date : 2025-02-25 19:08:35
Copyright for syndicated content belongs to the linked Source.
